http://www.twitter.comTwitter is a service for friends, family, and co-workers to communicate and stay connected through the exchange of quick, frequent answers to one simple question: What are you doing?
View Older Stories View More Recent Stories
-
Aethlon Medical Announces Fiscal 2017 Results
-
Aethlon Medical To Release 2017 Fiscal Year End Financial Results and Host Conference Call on June 28, 2017
-
Aethlon Medical To Present Clinical Study Results at The BIO International Convention
-
Aethlon Medical, Inc., Announces Upcoming Presentation and Webcast at the LD Micro Invitational Conference on June 6, 2017
-
Aethlon to Present at the LD Micro Invitational Conference on June 6, 2017
-
Aethlon Medical Releases Shareholder Update
-
Aethlon Medical Discloses Tech Nation Interview On National Public Radio
-
Aethlon Medical (AEMD) Concludes Hemopurifier Clinical Study
-
Aethlon Medical Announces The Conclusion Of Hemopurifier Clinical Study
-
Aethlon Medical To Present At ROTH Capital Partners 29th Annual Growth Stock Conference On March 14, 2017
-
Aethlon Medical (AEMD) Reports European Patent Protecting Methods of Quantifying Exosomes
-
Aethlon Medical Announces the Grant of a European Patent Protecting Methods of Quantifying Exosomes
-
Aethlon Medical CEO Note: Bill Gates on the Threat of Bioterrorism
-
Aethlon Medical (AEMD) Says Results of Study Show Ability of Aethlon Hemopurifier to Capture Latent Viral Pathogens
-
Aethlon Medical Reports Results of Cytomegalovirus, Epstein-Barr and Herpes Simplex Virus Studies
-
Aethlon Medical Announces Fiscal 2017 Third Quarter Results
-
Aethlon Medical To Host Third Quarter Fiscal 2017 Investor Call On February 10, 2017
-
Researchers Announce Plans for Study of Candidate Blood Test to Detect Chronic Traumatic Encephalopathy (CTE) in Former NFL Players
-
CEO Note - Clinical Study Update and a Review of 2016 Accomplishments
-
Passage of the 21st Century Cures Act and its Potential Implications on Biodefense
-
Aethlon Medical (AEMD) Initiates Research Study to Validate Ability of Aethlon Hemopurifier to Capture Viruses in Sepsis Patients
-
Aethlon Announces Initiation of Sepsis-Related Virus Study
-
Aethlon Medical Announces Fiscal 2017 Second Quarter Results
-
Aethlon Medical To Host Second Quarter Fiscal 2017 Investor Call On November 10, 2016
-
Aethlon Medical (AEMD) Announces Completion of Multiple DARPA Milestones
-
Aethlon Medical Achieves DARPA Milestones, Including Middle East Respiratory Syndrome Coronavirus (MERS-CoV) Validation
-
Aethlon Medical Announces Corporate Update Presentation At Next Week's 2016 Bio Investor Forum
-
Aethlon Medical Updates Corporate Presentation Schedule
-
Aethlon Medical To Present At The Rodman & Renshaw 18th Annual Global Investment Conference On September 13, 2016
-
The Dilemma in Funding Zika and Other Pandemic Therapies
-
The Dilemma in Funding Zika and Other Pandemic Therapies
-
Aethlon Medical Announces Upcoming September Investor And Industry Conferences
-
Aethlon Medical Announces Upcoming September Investor And Industry Conferences
-
Aethlon Medical Announces Fiscal 2017 First Quarter Results
-
Aethlon Medical (AEMD) Announces Positive Hemopurifier in vitro Study Data in Zika Virus
-
Aethlon Medical Announces Zika Virus Data
-
Aethlon Medical To Host First Quarter Fiscal 2017 Investor Call On August 11, 2016
-
Aethlon Medical Announces Fiscal 2016 Results
-
Aethlon Medical (AEMD) Files for $12.5M Common Stock At The Market Sales Program
-
Aethlon Medical Announces $12.5 Million At The Market Program
-
Aethlon Medical Joins Russell Microcap® Index
-
Aethlon Medical to Host Fourth Quarter and Full Year Fiscal 2016 Investor Call On June 29, 2016
-
Aethlon Medical Set To Join Russell Microcap® Index
-
Aethlon Medical Announces Issuance Of Exosome Capture Patent
-
Aethlon Medical To Present Cancer And Infectious Disease Initiatives, As Well As Chronic Traumatic Encephalopathy (CTE) Candidate Biomarker Discovery At Tomorrow's BIO International Convention
-
Aethlon Medical To Present At 2nd Annual Sachs Associates Immuno-oncology: BD&L And Investment Forum On June 3, 2016
-
Aethlon Medical's Exosome Sciences Announces Production of ELLSA Exosome Isolation Platform
-
Aethlon Medical (AEMD) CEO Note: Hemopurifier Clinical Progression, USA Today on the Next Zika, Combating Bioterror & Pandemic Threats
-
Aethlon Medical (AEMD) Discloses Hemopurifier Trial and Manufacturing Advancements, Says Study Back on Track
-
Aethlon Medical Discloses Hemopurifier® Clinical Trial and Manufacturing Advancements

